Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 893

1.

Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.

Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 15;12(4):335-48. Epub 2011 Aug 15.

PMID:
21785270
3.
4.

Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.

Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C.

Oncogene. 2006 Aug 24;25(37):5145-54. Epub 2006 Apr 24.

PMID:
16636678
5.

TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.

Zhang Y, Zhang B.

Mol Cancer Res. 2008 Dec;6(12):1861-71. doi: 10.1158/1541-7786.MCR-08-0313.

6.

2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.

Stolfi C, Caruso R, Franzè E, Rizzo A, Rotondi A, Monteleone I, Fantini MC, Pallone F, Monteleone G.

Mol Cancer Ther. 2011 Oct;10(10):1969-81. doi: 10.1158/1535-7163.MCT-11-0316. Epub 2011 Aug 4.

7.
8.

Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.

Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL.

Clin Cancer Res. 2008 May 15;14(10):3168-76. doi: 10.1158/1078-0432.CCR-07-4362.

10.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.

Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS.

Neurosurg Focus. 2002 Sep 15;13(3):ecp1.

PMID:
15844877
11.

Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.

Lin T, Ding Z, Li N, Xu J, Luo G, Liu J, Shen J.

Eur J Cancer. 2011 Aug;47(12):1890-907. doi: 10.1016/j.ejca.2011.04.004. Epub 2011 May 10.

PMID:
21565489
12.

Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.

Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B.

Mol Cancer Res. 2009 Nov;7(11):1835-44. doi: 10.1158/1541-7786.MCR-09-0244. Epub 2009 Oct 20.

13.

Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.

Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H.

Cancer Res. 2010 Feb 1;70(3):1101-10. doi: 10.1158/0008-5472.CAN-09-2889. Epub 2010 Jan 26.

15.

The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.

Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, Wang Y, He L, Qian C, Qian Q, Liu X.

Cancer Gene Ther. 2006 Nov;13(11):1011-22. Epub 2006 Jun 23.

PMID:
16799468
16.

Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.

Bertram H, Nerlich A, Omlor G, Geiger F, Zimmermann G, Fellenberg J.

Mod Pathol. 2009 Jul;22(7):895-905. doi: 10.1038/modpathol.2009.39. Epub 2009 Mar 20.

17.

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.

Cancer Res. 2005 Jun 1;65(11):4799-808.

18.
19.

Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y.

Neuro Oncol. 2010 Jul;12(7):687-700. doi: 10.1093/neuonc/nop069. Epub 2010 Feb 11.

20.

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R, Albert V, Muto M, Yoshida H, Aoki M, Tamada T, Kuroki R, Yoshida H, Ishida I, Ware CF, Kataoka S.

Clin Cancer Res. 2005 Apr 15;11(8):3126-35.

Supplemental Content

Support Center